Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | MC5R | P33032 | 5/20 | 0.53 |
| ▸ | MC4R | P32245 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | MC3R | P41968 | 3/20 | 0.50 |
| ▸ | MC1R | Q01726 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22495340 | 0.84 | GAA (0.63) | CA1CA2MC5RMC4RCA12 | |
| SCHEMBL3240039 | 0.83 | GAA (0.67) | CA1CA2CA12CA4KMT2A | |
| SCHEMBL20902780 | 0.82 | CA1 (0.71) | CA1CA2CA12KMT2AGAA | |
| SCHEMBL3232261 | 0.79 | CA1 (0.53) | CA1CA2KMT2AGAAKDM4E | |
| SCHEMBL5177357 | 0.79 | BCHE (0.65) | CA1CA2KMT2AGAAKDM4E | |
| SCHEMBL3243773 | 0.78 | TAAR1 (0.54) | CA1CA2KMT2AGAAKDM4E | |
| SCHEMBL3571060 | 0.78 | HDAC1 (0.62) | CA1CA2GAAMAPTCYP1A2 | |
| SCHEMBL5178076 | 0.78 | TAAR1 (0.54) | CA1CA2KMT2AKDM4EMEN1 | |
| SCHEMBL5177175 | 0.78 | CA1 (0.52) | CA1CA2KMT2AGAAKDM4E | |
| SCHEMBL3240005 | 0.78 | BCHE (0.70) | KMT2ABCHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | claimed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | CA1 1280/4885CA2 411/4885MC5R 279/4885 |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | CA1 4644/4885CA2 4559/4885MC5R 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.